Telormedix Appoints Nick Rogerson as New Chairman of the Board
Telormedix announced the appointment of Nicholas Ralphe Rogerson as the Company’s Chairman of the Board.
Nicholas Rogerson has worked in the pharmaceutical industry for nearly 25 years in major companies as well as in consulting and investment banking. He specialises in business development and advises pharma and biotech companies, investment banks and venture capitalists on issues such as partnering, M&A and strategic exits. Following an early scientific career, he started in regulatory affairs and then rapidly progressed to business development. Mr. Rogerson has been Global Head of Pharmaceutical Business Development at Hoffmann-La Roche, Head of Corporate M&A for Novartis and Managing Director for Bear Stearns, leading their European Pharma M&A efforts. Mr. Rogerson has an MBA from Cranfield University School of Management (UK) as well as BSc & MSc life-sciences degrees from Sheffield and London Universities respectively. He is also a graduate of The Wharton School's AMP (Advanced Management Program) in the USA.
Other news from the department people
